Evotec Stock

Evotec Revenue

The The revenue of Evotec (EVT.DE) as of Mar 14, 2026 is 842.74 M EUR. In the previous year, The revenue was 786.66 M EUR — a change of 7.13% (higher).

Revenue

842.74 MEUR

YoY

7.13%

Last updated: Mar 14, 2026

In 2026, Evotec's sales reached 842.74 M EUR, a 7.13% difference from the 786.66 M EUR sales recorded in the previous year.

The Evotec Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

REVENUE (B EUR)
GROSS MARGIN (%)
Date
REVENUE (B EUR)
GROSS MARGIN (%)
Jan 1, 2005
0.08 base
3,634 base
Jan 1, 2006
0.07 base
3,412 base
Jan 1, 2007
0.03 base
2,432 base
Jan 1, 2008
0.04 base
4,444 base
Jan 1, 2009
0.04 base
4,309 base
Jan 1, 2010
0.06 base
4,394 base
Jan 1, 2011
0.08 base
4,370 base
Jan 1, 2012
0.09 base
3,551 base
Jan 1, 2013
0.09 base
3,632 base
Jan 1, 2014
0.09 base
3,283 base
Jan 1, 2015
0.13 base
2,751 base
Jan 1, 2016
0.16 base
3,559 base
Jan 1, 2017
0.26 base
3,101 base
Jan 1, 2018
0.38 base
2,984 base
Jan 1, 2019
0.45 base
2,977 base
YEARREVENUE (B EUR)GROSS MARGIN (%)
2031 est 1.0610,80
2030 est 1.0810,65
2029 est 1.0311,16
2028 est 0.9711,89
2027 est 0.9312,31
2026 est 0.8413,63
2025 est 0.7914,60
2024 0.814,41
2023 0.7822,40
2022 0.7523,16
2021 0.6224,52
2020 0.525,10
2019 0.4529,77
2018 0.3829,84
2017 0.2631,01
2016 0.1635,59
2015 0.1327,51
2014 0.0932,83
2013 0.0936,32
2012 0.0935,51
2011 0.0843,70
2010 0.0643,94
2009 0.0443,09
2008 0.0444,44
2007 0.0324,32
2006 0.0734,12
2005 0.0836,34
API Docs Get API Key

Evotec Revenue

Evotec Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2005
79.8 M EUR
-16.9 M EUR
-33.6 M EUR
Jan 1, 2006
67.4 M EUR
-30.8 M EUR
-32.5 M EUR
Jan 1, 2007
32.9 M EUR
-49.2 M EUR
-11.2 M EUR
Jan 1, 2008
39.6 M EUR
-45.5 M EUR
-78.3 M EUR
Jan 1, 2009
42.7 M EUR
-19.6 M EUR
-45.5 M EUR
Jan 1, 2010
55.3 M EUR
1.7 M EUR
3.3 M EUR
Jan 1, 2011
80.1 M EUR
5.8 M EUR
6.7 M EUR
Jan 1, 2012
87.3 M EUR
300,000 EUR
2.5 M EUR
Jan 1, 2013
85.9 M EUR
4.1 M EUR
-25.4 M EUR
Jan 1, 2014
89.5 M EUR
2.14 M EUR
-6.98 M EUR
Jan 1, 2015
127.68 M EUR
-2.53 M EUR
16.52 M EUR
Jan 1, 2016
164.51 M EUR
36.75 M EUR
27.53 M EUR
Jan 1, 2017
263.77 M EUR
37.91 M EUR
23.48 M EUR
Jan 1, 2018
375.41 M EUR
66.43 M EUR
84.17 M EUR
Jan 1, 2019
446.44 M EUR
74.51 M EUR
38.07 M EUR

Evotec Margins

Evotec stock margins

The Evotec margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Evotec. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Evotec.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2005
36.34 %
-21.18 %
-42.11 %
Jan 1, 2006
34.12 %
-45.7 %
-48.22 %
Jan 1, 2007
24.32 %
-149.54 %
-34.04 %
Jan 1, 2008
44.44 %
-114.9 %
-197.73 %
Jan 1, 2009
43.09 %
-45.9 %
-106.56 %
Jan 1, 2010
43.94 %
3.07 %
5.97 %
Jan 1, 2011
43.7 %
7.24 %
8.36 %
Jan 1, 2012
35.51 %
0.34 %
2.86 %
Jan 1, 2013
36.32 %
4.77 %
-29.57 %
Jan 1, 2014
32.83 %
2.39 %
-7.8 %
Jan 1, 2015
27.51 %
-1.98 %
12.94 %
Jan 1, 2016
35.59 %
22.34 %
16.73 %
Jan 1, 2017
31.01 %
14.37 %
8.9 %
Jan 1, 2018
29.84 %
17.69 %
22.42 %
Jan 1, 2019
29.77 %
16.69 %
8.53 %

Evotec Stock analysis

What does Evotec do? Evotec SE is a biotechnology company based in Hamburg that specializes in the development of drug compounds for the pharmaceutical and biotech industries. The company was founded in 1993 as part of a research project at the University of Hamburg and has since become one of the leading drug discovery and development companies globally. Evotec's business model is based on collaborating with its customers, primarily large pharmaceutical companies, to develop new and innovative drugs. Evotec offers its extensive expertise in drug discovery and acts as a service provider. The company has modern laboratories equipped with state-of-the-art scientific methods and technologies. Customers benefit from the scientists' years of experience and collaboration with renowned academic institutions worldwide. Evotec operates in the Discovery, Development, and Manufacturing segments, providing a wide range of services to its customers. In the Discovery segment, the focus is on identifying drug candidates and preclinical development of drugs using advanced technologies and research methods. In the Development segment, Evotec supports its customers in the planning, execution, and analysis of clinical trials. The close collaboration with customers allows Evotec's scientists to respond quickly and effectively to feedback and requirements. The Manufacturing segment involves the industrial production of drugs. Evotec offers a broad range of products, including both its own and customer-requested drug compounds. One example is the drug DiaPep277 for the treatment of Type 1 diabetes. DiaPep277 was developed by Evotec in collaboration with Israeli company Andromeda Biotech and is now distributed by Teva Pharmaceuticals. Another example is the drug EVT307, which was developed by Evotec in collaboration with pharmaceutical company Boehringer Ingelheim and is currently being tested in Phase II clinical trials for the treatment of schizophrenia. Evotec's success is also based on its expertise in the production of small molecules. Small molecules are drug compounds characterized by their small size and highly specific binding to target proteins. In contrast, the production of large molecules such as antibodies or biologics is more complex and expensive in development due to their size. Evotec's success story continues: In 2019, the company achieved record results, increasing its revenue by 23 percent to 446.4 million euros. The number of employees has also steadily grown in recent years and now exceeds 3,000 employees worldwide. Evotec is considered one of the most successful biotechnology companies in Europe today. Evotec is one of the most popular companies on Eulerpool.com.

Revenue Details

Understanding Evotec's Sales Figures

The sales figures of Evotec originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Evotec’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Evotec's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Evotec’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Evotec stock

The revenue of Evotec amounted to 786.66 M EUR 842.74 M

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Income Statement — Evotec

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

All Key Metrics — Evotec